Rahul Khara

Dr. Khara joins Disc Medicine from Acceleron where he served as Vice President, Legal and Chief Compliance Officer. In this role, he led the commercial legal and compliance functions. While at Acceleron, Dr. Khara led or supported a wide range of legal matters including facilitating the launch of Reblozyl® (luspatercept-aamt), Acceleron’s first commercial product, building the company’s commercial compliance program, and the successful acquisition of the company by Merck. Prior to Acceleron, Dr. Khara worked at the law firms of Arnold & Porter LLP and Sidley Austin LLP, where he helped biopharma companies in various stages of development navigate legal issues related to the clinical development of new assets, launch of new drug products, business development transactions, compliance, and enforcement. Dr. Khara received a Pharm.D. from the Ernest Mario School of Pharmacy at Rutgers University and a J.D. from the University of Michigan Law School.